Abstract. Polymorphisms in the cytochrome P (CYP) 450 family may cause adverse drug responses in individuals.
Introduction
The cytochrome P450 enzymes have an important role in the metabolism of various therapeutic agents, in which different enzymatic activities lead to variability in drug responses among individuals (1) . Cytochrome P450 2C19 (CYP2C19) is a highly polymorphic isoenzyme of the cytochrome P450 superfamily, affecting the metabolism of an extensive range of therapeutic drugs (2) . The CYP2C19 gene, which includes nine exons and eight introns, is located at the 10q24.1-10q24.3 locus of chromosome 10, where coding sequences is 1,473 bp and resulting in a protein of 490 amino acid residues (3, 4) . Approximately 25 genetic variants in the exonic region of the CYP2C19 have been identified (4) . CYP2C19 is involved in metabolizing several important therapeutic drugs, including omeprazole, lansoprazole, proguanil, propranolol, imipramine, mephenytoin, chloroguanide, hexabarbitone, diazepam and certain antidepressants (1, 5) . Common variants of the CYP2C19 gene are associated with impaired drug metabolism. CYP2C19*2 and CYP2C19*3 were identified in individuals who exhibited a reduced capability for metabolizing the probe drugs, and variant CYP2C19*17 is associated with ultra-rapid metabolism of CYP2C19 substrates (3).
The principal detrimental allele, CYP2C19*2, results from a guanine (G) to adenine (A) transition at position 681 in exon 5 (rs4244285), producing an aberrant splice site and it represents the most frequent CYP2C19 defect in all populations (6) . CYP2C19*2 and CYP2C19*3 are the most common alleles, encoding enzymes with decreased activity (7) . CYP2C19*3 (636G>A) is considered the most important allele, in which a point mutation in exon 4 results in a premature stop codon, and therefore nonfunctional protein (1, 4) .
The prevalence of the CYP2C19 poor metabolizer (PM) phenotype is 2-5% among Caucasians and Africans, and ~15% in Asians (8) , while CYP2C19*3 is considered to be an Asian mutation (1) . CYP2C19*2 and *3 alleles have been proposed to explain <50%, to >90%, of the PM phenotype (2) .
The CYP2C19*17 allele was previously reported to be associated with high CYP2C19 activity, and identified at 18-28% in European populations, in 17-18% of Africans and in 0.3-4% of Asian populations (9) . CYP2C19*17 is a -806 C>T single nucleotide polymorphism that causes specific nuclear protein binding to the 5'-flanking region. This binding results in increased gene transcription and high enzyme activities (10) .
In this study, the frequency of the CYP2C19*2, *3, and *17 was examined among an Iranian cohort of different ethnicities. 13 Lure and 14 Kurd individuals to examine the CYP2C19*17 allele. Blood samples (2 ml) with ethylenediaminetetraacetic acid were collected from participants. Informed consent to participate in genetic and molecular analyses, and consent to publish results were obtained from individuals. The Medical Ethics Committee of the SMC specifically approved this study (approval no. AA/27/2008). The exclusion criteria to select individuals in this study were any background of familial and sporadic cancer, metabolic, nuclear and mitochondrial DNA-associated disorders.
Materials and methods

Specimen collection and ethical approval.
Genomic DNA extraction and primer sequences. Genomic DNA from blood samples was extracted using the MBST salting-out kit (CinnaGen, Tehran, Iran). The oligonucleotide forward and reverse primers used for the amplification of CYP2C19*2, *3, and *17 alleles were from previous published studies as follows: CYP2C19*2, forward 5'-AAT TAC AAC CAG AGC TTGGC-3' and reverse 5'-TAT CAC TTT CCA TAA AAG CAAG-3' (11); CYP2C19*3, forward 5'-AAC ATC AGG ATT GTA AGCAC-3' and reverse 5'-TCA GGG CTT GGT CAA TATAG-3' (11); and CYP2C19*17, forward 5'-GCC CTT AGC ACC AAA TTCTC-3' and reverse 5'-ATT TAA CCC CCT AAA AAA ACA CG-3' primers (10) .
Restriction fragment length polymorphism (RFLP).
Genotyping analysis of the CYP2C19*2, *3 and *17 alleles was performed using polymerase chain reaction-RFLP (PCR-RFLP). The PCR amplification was performed using 60 ng genomic DNA, 0.3 U Taq DNA polymerase (CinnaGen), 5 pmol each primers, 10X PCR buffer, 1.5 mM MgCl 2 and 0.5 mM dNTP. The reaction mixture was initially denatured at 95˚C for 3 min, followed by 35 cycles of 95˚C for 1 min, 54˚C for 1 min, and 72˚C for 2 min for CYP2C19*2; 35 cycles of 94˚C for 50 sec, 54.2˚C for 50 sec, and 72˚C for 50 sec for CYP2C19*3; 35 cycles of 94˚C for 1 min, 56.3˚C for 1 min, and 72˚C for 1 min for CYP2C19*17; and all had and a final extension at 72˚C for 10 min.
The 168-bp, 119-bp and 473-bp amplified fragments for *2, *3 and *17 alleles, respectively, were run on a 1.5% agarose gel and then stained using silver nitrate (CinnaGen) prior to restriction digestion. Restriction endonucleases, including SmaI, BamHI or LweI, were then added to PCR products in a 31 µl reaction volume consisting of 10 µl PCR products, 2 µl 10X SmaI or BamHI or LweI buffer (Thermo Fisher Scientific, Inc.), 1 µl SmaI or BamHI or LweI enzyme (Thermo Fisher Scientific, Inc.) and 18 µl double distilled water, and were then incubated at 37˚C for 16 hr. The digested PCR products were separated by 8% polyacrylamide gel electrophoresis (PAGE) at 180 V for 110 min. The DNA bands were then visualized using silver nitrate staining. The PCR products with length of 168-bp, 119-bp, and 473-bp were subsequently digested with restriction endonuclease SmaI, BamHI, and LweI, respectively.
Single-strand conformation polymorphism (SSCP).
The PCR-amplified DNA fragments were denatured prior to loading on a polyacrylamide gel. Briefly, 10 µl PCR mixture was mixed with 7 µl denaturation buffer (990 µl of 100% formamide, 10 µl of 1 M sodium hydroxide, and a few granules of bromophenol blue). Samples were then incubated at 45˚C for 30 min, and 12 µl SSCP color (CinnaGen) was added to sample after 23 min. The samples were analyzed using 6% PAGE at 80 V for 16 h for *2 and *3, and 150 V for 16 h for *17 and then stained by silver nitrate. The homozygous (as mutated or wild type) and heterozygous variants of the CYP2C19*2, *3, and *17 were identified as several bands.
Sequencing analysis. The PCR products were sequenced with forward and reversed primers on an automated ABI 3100 sequencing machine (Applied Biosystems, Kavosh Fanavaran Kawsar Company, Iran). All DNA fragments were then sequenced and analyzed using the Finch TV program (Geospiza, Inc., Seattle, WA, USA) in order to confirm any nucleotide variations (Fig. 1) .
Statistical analysis. The statistical analyses were conducted using SPSS (version 22; IBM Corp., Armonk, NY, USA) software to perform χ 2 analysis of the association between the frequency of alleles among the different ethnicities within the Iranian population and confidence interval test (95%) was used to calculate the frequency of alleles. P<0.05 was considered to indicate a statistically significant difference.
Results
Allelic and genotypic frequency distributions of CYP2C19*2, *3 and *17 were analyzed using blood samples of 1,229 unrelated healthy individuals from the Iranian population with different ethnicities. The homozygous (mutated and wild type) and heterozygous variants of the CYP2C19*2, *3 and *17 were analyzed using the PCR-RFLP and PCR-SSCP Table I ; Fig. 4 ).
Discussion
The present study provides comprehensive data regarding distribution of the allelic and genotypic frequency of the CYP2C19 among Iranian population of different ethnicities. The variant alleles of the CYP2C19 family including CYP2C19*2, CYP2C19*3 and CYP2C19*17 are associated with variation in adverse drug reactions among populations according to race and ethnic backgrounds. Many of these polymorphic genes encode inactive enzymes that may cause adverse drug reactions among individuals because of their poor metabolic activities (12) . CYP2C19 is the main factor for the metabolism of drugs, including omeprazole, lansoprazole, imipramine, propranolol, mephenytoin, chloroguanide, hexabarbitone, diazepam, proguanil and certain antidepressants (1, 5) . Polymorphisms in CYP2C19 may produce non-functional alleles and therefore no enzyme Table I . Statistical analysis of the CYP2C19 (*2, *3 and *17) allelic and genotypic frequencies (%) among different ethnic groups in Iran. activity to metabolize these drugs correctly. The most important alleles, CYP2C19*2, CYP2C19*3 and CYP2C19*17, carry polymorphisms at 681 G>A in exon 5, 636 G>A in exon 4 and -806 C>T in the 5' flanking region, respectively (3,13,14). CYP2C19*2 results in a splicing defect, CYP2C19*3 in a premature stop codon and CYP2C19*17 in increased gene transcription (13, 14) . CYP2C19*2 is the most common allele among the Asian population and its prevalence is varies in different region of Asia. The CYP2C19*2 allele was observed with a frequency of 21.4% in the Iranian population, which is higher than the Swedish (14.4%) (15) , German (15%) (16), Ethiopian (13.6%) (17) and Zimbabwean (13.1%) (18) populations, while not as high as reported in other populations, including Japanese (23%) (19) and Chinese-Taiwanese (32%) (19) . The population with most frequent detection of the CYP2C19*2 allele in the previous reports that were examined was Filipino (39%; Table II ). The prevalence of the CYP2C19*2 increases steeply from Western Asia and Iran to India, reaching its maximum (>75%) in Melanesian populations (20) .
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CYP2C19 is a clinically impor tant enzyme in metabolism of different drugs, including antiplatelet drug, clopidogrel. Among individuals treated with clopidogrel, carriers of CYP2C19*2, CYP2C19 reduced-function alleles, exhibited markedly lower levels of the active metabolite of the drug, decreased platelet inhibition, and a higher rate of subsequent cardiovascular events, compared with non-carriers. However, the CYP2C19*17 allele is reported significantly related with an increased response to clopidogrel and high risk of bleeding. Thus, identification and functional analysis of CYP2C19 genetic polymorphisms are important for improving the understanding of safer drug therapy (2) .
Furthermore, the CYP2C19*3 allele was observed with a prevalence of 1.7% among the Iranian population in the present study, which is higher than the previously reported frequency in the Canadian (0%) (21) and Danish (0%) (22) populations, but not as high as reported in other populations, including Japanese (10.4%) (19) and Korean (11.6%) (23) , and was demonstrated to be of an approximately similar frequency to the Ethiopian population (1.8%; Table II) (17) .
The frequency of CYP2C19*3 as an Asian mutation (1) increases from the west to the east of Asia (Table II; Fig. 5 ). According to previous studies, the highest frequency of the CYP2C19*3 allele was reported in the Indonesian populations Frequency of the CYP2C19*3 allele in different countries around the world. The highest incidence of the CYP2C19*3 allele has been reported in Indonesians (37%). The second highest CYP2C19*3 frequency has been reported in the Iruna population from New Guinea (34%). It seems that the allelic frequency of CYP2C19*3 increases from the west to the east of Asia. CYP2C19, cytochrome P450 2C19.
of South-East Asia (37%) (24) , followed by the Iruna population from New Guinea (34%; Fig. 5) (24) . These results suggest that the prediction of the CYP2C19*3 allele is necessary in drug research and therapy, and the effects of the CYP2C19*3 allele on drug metabolism should be investigated, because side effects of drugs are comparatively common among these countries (25, 26) . In fact, individuals with CYP2C19*3 (A/A) genotype have no ability to metabolize drugs completely, consequently resulting in incomplete and poor metabolism of the drugs, drug accumulation in the blood and drug toxicity. In the current study, the CYP2C19*17 allele was identified with a prevalence of 27.1% among the Iranian population, which was higher than most countries included in Table III , including the Danish (20.1%) (27) and Norwegian (22%) (28) population, and was similar in frequency to the Polish population (27.2%) (29) .
In summary, the determination of the allelic and genotypic frequencies of the CYP2C19 gene among different ethnicities may provide data to be used to personalize treatments in order to improve the efficiency of the therapeutic outcomes and decrease the appearance of adverse effects, and therefore, facilitate the advancement of personalized medicine. Genotyping of the CYP2C19*2, *3 and *17 alleles among different ethnicities within the Iranian population, including Fars, Turks, Caspians, Lures and Kurds is an important for avoiding the side effect of drugs and drug interactions, and may lead to improved survival and decreased drug modality risk.
